The Pathogenesis of Type 1 Diabetes.

Abstract

Type 1 diabetes (T1D) is a chronic autoimmune disease with a metabolic outcome. Studies over the past decades, have identified the contributions of genetics, environmental factors, and disorders of innate and adaptive immunity that collectively cause β-cell killing. The risk for T1D can be genetically identified but genotypes alone do not identify factors that lead to disease progression. The incidence of T1D has been increasing in the past few decades, which may be due to reduced exposure to infections and other environmental factors that can reduce autoimmunity (hygiene hypothesis). Once initiated, the disease pathogenesis progresses through stages that have been defined on the bases of immunologic (i.e., autoantibodies) and metabolic markers (glucose tolerance). The stages only loosely capture the risk for the time to diagnosis of disease, do not directly reflect disease activity, and there may be variance in the rate of progression within stages. In a general way, the stages can be used to identify patients at risk in whom interventions may be considered to modulate progression. This was achieved with the approval of teplizumab, a humanized anti-CD3 monoclonal antibody, for delaying the diagnosis of T1D.